Serotherapy as Graft-Versus-Host Disease Prophylaxis in Haematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukaemia

Serotherapy comprising agents such as anti-thymocyte globulin, anti-T-lymphocyte globulin, and the anti-CD52 monoclonal antibody alemtuzumab is used widely to reduce the incidence of graft-versus-host disease (GvHD) after paediatric haematopoietic stem cell transplantation (HSCT). The outcome of tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Keogh, Steven J., Dalle, Jean-Hugues, Admiraal, Rick, Pulsipher, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771860/
https://www.ncbi.nlm.nih.gov/pubmed/35071142
http://dx.doi.org/10.3389/fped.2021.805189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771860/
https://www.ncbi.nlm.nih.gov/pubmed/35071142
http://dx.doi.org/10.3389/fped.2021.805189

Ejemplares similares